Loading…
MARKETS
TOOLS
LEARN
Equiscale · Syntellia LLC
QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point of Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, to measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions. The Transfusion Medicine business unit offers immunohematology instruments and tests used for blood typing to ensure patient-donor compatibility in blood transfusions; and donor screening instruments and tests used for blood and plasma screening for infectious diseases. The Point of Care business unit provides instruments and tests to provide rapid results across a continuum of POC settings. The Molecular Diagnostics business unit offers polymerase chain reaction thermocyclers; amplification systems; and sample-to-result molecular instruments and tests for syndromic infectious disease diagnostics. The company sells its products directly to end users through a direct sales force; and through a network of distributors for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, blood banks, and donor centers, as well as for individual, non-professional, and over-the-counter use. It operates in North America, Europe, the Middle East, Africa, China, Japan and Asia Pacific, and Latin America. The company was incorporated in 1979 and is headquartered in San Diego, California.
Rule-based from financial data. Not advice.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $2.7B | $-483M | $-1.1B | $-83M | -58.9% | -1.9% | -44.8% |
| 2024 | $2.8B | $-1.5B | $-2.1B | $-112M | -68.8% | -7.2% | 20216.8% |
| 2023 | $3.0B | $607M | $-10M | $71M | -0.2% | -8.2% | -101.8% |
| 2022 | $3.3B | $1.1B | $549M | $744M | 11.1% | - | - |
| 2021 | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total Revenue | - | 3,266 | 2,997.80 | 2,782.90 | 2,730.20 |
| Operating Revenue | - | 3,266 | 2,997.80 | 2,782.90 | 2,730.20 |
| Cost Of Revenue | - | 1,329.80 | 1,500.70 | 1,496.40 | 1,456 |
| Gross Profit | - | 1,936.20 | 1,497.10 | 1,286.50 | 1,274.20 |
| Operating Expense | - | 953.70 | 1,240.10 | 1,240.70 | 1,219.40 |
| Research And Development | - | 187.90 | 245 | 218.70 | 186.20 |
| Selling General And Administration | - | 621 | 763.20 | 766.80 | 746.30 |
| Total Expenses | - | 2,283.50 | 2,740.80 | 2,737.10 | 2,675.40 |
| Operating Income | - | 982.50 | 257 | 45.80 | 54.80 |
| Total Operating Income As Reported | - | 843.70 | 139.10 | -1,960.90 | -919.20 |
| EBITDA | - | 1,094 | 607 | -1,489.80 | -482.60 |
| Normalized EBITDA | - | 1,257.20 | 695.80 | 491.50 | 488.50 |
| EBIT | - | 810.40 | 149.80 | -1,943.20 | -924.60 |
| Interest Income | - | 1.30 | 5.50 | 2.60 | 2.20 |
| Interest Expense | - | 74.50 | 178.90 | 188.30 | 183.10 |
| Net Interest Income | - | -75.30 | -176.70 | -188.90 | -185.60 |
| Other Non Operating Income Expenses | - | -8.10 | -20.60 | -7.10 | -5.80 |
| Other Income Expense | - | -171.30 | -109.40 | -1,988.40 | -976.90 |
| Interest Income Non Operating | - | 1.30 | 5.50 | 2.60 | 2.20 |
| Interest Expense Non Operating | - | 74.50 | 178.90 | 188.30 | 183.10 |
| Net Non Operating Interest Income Expense | - | -75.30 | -176.70 | -188.90 | -185.60 |
| Pretax Income | - | 735.90 | -29.10 | -2,131.50 | -1,107.70 |
| Tax Provision | - | 187.20 | -19 | -79.50 | 24.10 |
| Tax Rate For Calcs | - | 0 | 0 | 0 | 0 |
| Tax Effect Of Unusual Items | - | -41.45 | -18.65 | -73.31 | -203.93 |
| Net Income Continuous Operations | - | 548.70 | -10.10 | -2,052 | -1,131.80 |
| Net Income From Continuing And Discontinued Operation | - | 548.70 | -10.10 | -2,052 | -1,131.80 |
| Net Income From Continuing Operation Net Minority Interest | - | 548.70 | -10.10 | -2,052 | -1,131.80 |
| Net Income | - | 548.70 | -10.10 | -2,052 | -1,131.80 |
| Net Income Common Stockholders | - | 548.70 | -10.10 | -2,052 | -1,131.80 |
| Net Income Including Noncontrolling Interests | - | 548.70 | -10.10 | -2,052 | -1,131.80 |
| Normalized Income | - | 670.45 | 60.05 | -144.01 | -364.63 |
| Diluted NI Availto Com Stockholders | - | 548.70 | -10.10 | -2,052 | -1,131.80 |
| Basic Average Shares | - | 56.80 | 66.80 | 67.20 | 67.80 |
| Diluted Average Shares | - | 57.40 | 66.80 | 67.20 | 67.80 |
| Reconciled Depreciation | - | 283.60 | 457.20 | 453.40 | 442 |
| Reconciled Cost Of Revenue | - | 1,178.70 | 1,248.30 | 1,246.40 | 1,203.20 |
| Total Unusual Items | - | -163.20 | -88.80 | -1,981.30 | -971.10 |
| Total Unusual Items Excluding Goodwill | - | -163.20 | -88.80 | -1,981.30 | -971.10 |
| Special Income Charges | - | -162.80 | -117.90 | -2,006.70 | -979.10 |
| Other Special Charges | - | 24 | - | - | 5.10 |
| Write Off | - | 2.80 | 4.50 | 56.90 | - |
| Impairment Of Capital Assets | - | 2.80 | 4.50 | 1,879.50 | 710.40 |
| Restructuring And Mergern Acquisition | - | 136 | 113.40 | 127.20 | 263.60 |
| Gain On Sale Of Security | - | -0.40 | 29.10 | 25.40 | 8 |
| Depreciation Amortization Depletion Income Statement | - | 132.50 | 204.80 | 203.40 | 189.20 |
| Depreciation And Amortization In Income Statement | - | 132.50 | 204.80 | 203.40 | 189.20 |
| General And Administrative Expense | 84.25 | - | - | - | - |
| Other Gand A | 84.25 | - | - | - | - |
| Total Other Finance Cost | - | 2.10 | 3.30 | 3.20 | 4.70 |
| Other Operating Expenses | - | 12.30 | 27.10 | 51.80 | 97.70 |
| Selling And Marketing Expense | 175.32 | - | - | - | - |
| Average Dilution Earnings | 0 | 0 | - | - | - |
| Amortization | - | 132.50 | 204.80 | 203.40 | 189.20 |
| Amortization Of Intangibles Income Statement | - | 132.50 | 204.80 | 203.40 | 189.20 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| QuidelOrtho Corporationthis co. | QDEL | $1.0B | -0.92 | 0.54 | -58.9% | -7.68 |
| Omada Health, Inc. | OMDA | $1.1B | -84.72 | 4.71 | -5.6% | -181.05 |
| Xeris Biopharma Holdings, Inc. | XERS | $1.1B | 1916.51 | 77.56 | 4.0% | 28.56 |
| Collegium Pharmaceutical, Inc. | COLL | $1.1B | 16.86 | 3.51 | 20.8% | 4.10 |
| CONMED Corporation | CNMD | $1.1B |
| - |
| - |
| - |
| - |
| - |
| - |
| 22.48 |
| 1.02 |
| 4.6% |
| 10.49 |
| Azenta, Inc. | AZTA | $1.1B | -18.88 | 0.61 | -3.2% | 20.85 |
| The Pennant Group, Inc. | PNTG | $1.0B | 35.40 | 3.15 | 8.9% | 24.38 |
| EyePoint, Inc. | EYPT | $1.0B | -4.43 | 3.36 | -75.8% | -4.13 |
| Artivion, Inc. | AORT | $1.0B | 103.65 | 2.26 | 2.2% | 18.87 |
| Peer Median | - | 19.67 | 3.25 | 3.1% | 14.68 | |
Historically, Nov has averaged the highest return (+6.1%); Apr the lowest (-14.1%).
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -4.9%Negative MonthJan 2026: -4.87% | -16.3%Negative MonthFeb 2026: -16.30% | -27.7%Negative MonthMar 2026: -27.75% | -25.1%Negative MonthApr 2026: -25.14% | +5.9%Positive MonthMay 2026: +5.85% | +34.6%Positive MonthJun 2026: +34.56% | -4.3%Negative MonthJul 2026: -4.28% | -17.7%*Negative MonthAug 2026: -17.71% | — | — | — | — |
| 2025 | -2.4%Negative MonthJan 2025: -2.45% | -8.0%Negative MonthFeb 2025: -7.98% | -12.6%Negative MonthMar 2025: -12.55% | -20.5%Negative MonthApr 2025: -20.53% | +10.4%Positive MonthMay 2025: +10.36% | -6.0%Negative MonthJun 2025: -6.03% | -20.1%Negative MonthJul 2025: -20.12% | +24.6%Positive MonthAug 2025: +24.63% | +2.6%Positive MonthSep 2025: +2.65% | -8.4%Negative MonthOct 2025: -8.35% | +1.3%Neutral MonthNov 2025: +1.33% | +4.4%Positive MonthDec 2025: +4.42% |
| 2024 | -7.0%Negative MonthJan 2024: -7.04% | -33.4%Negative MonthFeb 2024: -33.44% | +5.1%Positive MonthMar 2024: +5.13% | -15.4%Negative MonthApr 2024: -15.42% | +9.0%Positive MonthMay 2024: +8.98% | -24.8%Negative MonthJun 2024: -24.82% | +18.3%Positive MonthJul 2024: +18.27% | +7.5%Positive MonthAug 2024: +7.53% | +7.9%Positive MonthSep 2024: +7.93% | -16.6%Negative MonthOct 2024: -16.56% | +7.8%Positive MonthNov 2024: +7.75% | +8.7%Positive MonthDec 2024: +8.66% |
| 2023 | -0.1%Neutral MonthJan 2023: -0.07% | +1.6%Neutral MonthFeb 2023: +1.55% | +2.5%Positive MonthMar 2023: +2.47% | +1.0%Neutral MonthApr 2023: +0.97% | -5.3%Negative MonthMay 2023: -5.35% | -2.7%Negative MonthJun 2023: -2.68% | +5.4%Positive MonthJul 2023: +5.43% | -5.7%Negative MonthAug 2023: -5.72% | -11.3%Negative MonthSep 2023: -11.32% | -16.4%Negative MonthOct 2023: -16.37% | +12.5%Positive MonthNov 2023: +12.52% | +7.2%Positive MonthDec 2023: +7.23% |
| 2022 | -23.4%Negative MonthJan 2022: -23.43% | +2.4%Positive MonthFeb 2022: +2.35% | +6.3%Positive MonthMar 2022: +6.30% | -10.5%Negative MonthApr 2022: -10.53% | -5.6%Negative MonthMay 2022: -5.56% | +2.3%Positive MonthJun 2022: +2.26% | +5.0%Positive MonthJul 2022: +5.00% | -22.3%Negative MonthAug 2022: -22.32% | -9.8%Negative MonthSep 2022: -9.82% | +25.7%Positive MonthOct 2022: +25.66% | -2.5%Negative MonthNov 2022: -2.46% | -2.2%Negative MonthDec 2022: -2.21% |
| 2021 | — | — | — | — | +12.7%Positive MonthMay 2021: +12.71% | +8.5%Positive MonthJun 2021: +8.48% | +10.4%Positive MonthJul 2021: +10.42% | -8.8%Negative MonthAug 2021: -8.85% | +9.5%Positive MonthSep 2021: +9.46% | -5.9%Negative MonthOct 2021: -5.94% | +11.1%Positive MonthNov 2021: +11.14% | -8.5%Negative MonthDec 2021: -8.52% |
| Avg±SD |
Each cell is the percentage change in closing price from the end of the prior month to the end of this month. The bottom row shows the average return for that calendar month across the selected years, plus or minus one standard deviation — the range that historically contained roughly two-thirds of outcomes. Past monthly patterns are not a forecast of future returns.
This aggregates every month by calendar position — all Januaries together, all Februaries together, and so on — to show whether a given month has leaned positive or negative historically. ‘Simple’ counts each month as +1 or −1. ‘Weighted’ gives larger moves more influence: +2 above +10%, −2 below −10%. With only 6 years of history for this asset, each month’s score reflects a small number of observations — read it as a historical tendency, not a reliable seasonal pattern.
This tracks a running tally across the asset’s full price history: each month adds or subtracts based on whether it was positive or negative. A rising line means more positive months than negative so far; a flattening or falling line means recent months have leaned negative. This measures historical month-to-month consistency, not expected future performance.
Year-to-date return is calculated by dividing each day’s closing price by the price on January 1st of that year (or the asset’s first available price if it began trading mid-year). The custom average line shows the mean YTD return at each calendar day across the selected years. The standard deviation band shows the range within which returns have historically fallen — at 1 SD, roughly two-thirds of years; at 2 SD, roughly 95%. Past year-to-date patterns do not predict future returns. The average and standard deviation band are computed from the year set chosen in “Average from”, which is independent of which year lines are displayed. The current in-progress year is excluded from these calculations, since a partial year is not comparable to complete ones. Election-cycle groupings follow the US presidential calendar and are offered only for US and crypto assets.
